Literature DB >> 3129809

Plasminogen activator inhibitor 1 and plasminogen activator inhibitor 2 in various disease states.

E K Kruithof1, A Gudinchet, F Bachmann.   

Abstract

The association of increased PA-inhibitor (PAI) activity and of PAI-1 and PAI-2 antigen levels with different pathological conditions was studied in a collective of over 300 patients. PAI-1 and PAI-2 levels were measured by specific radioimmunoassays. A good correlation was observed of PAI activity with PAI-1 antigen (r = 0.718; p less than 0.0001) but not with PAI-2 (r = 0.070; n.s.). Both in the controls and in the patients, PAI activity and PAI-1 antigen showed an extremely large range of values. PAI activity ranged from 0.5 to 68 U/ml and PAI-1 antigen from 6 to 600 ng/ml. Increased PAI activity and PAI-1 antigen was observed in patients with malignant tumors, cardiovascular or thromboembolic disease, in the postoperative phase, with hepatic insufficiency, after trauma and after extracorporeal circulation. The large spectrum of disease states with increased PAI activity and PAI-1 antigen reinforces previous suggestions that PAI-1 is an acute phase reactant. After extracorporeal circulation, PAI activity and PAI-1 concentrations strongly increased within one hour, remained elevated for at least one week and returned to preoperation values within 7 days. PAI-2 values ranged from below detection limit (15 ng/ml), observed in half of the plasmas, to 485 ng/ml in a pregnant woman. High values of PAI-2 were only observed in pregnancy.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3129809

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  19 in total

Review 1.  Acquired and congenital clotting syndromes.

Authors:  F W Blaisdell
Journal:  World J Surg       Date:  1990 Sep-Oct       Impact factor: 3.352

2.  Metabolic factors, adipose tissue, and plasminogen activator inhibitor-1 levels in type 2 diabetes: findings from the look AHEAD study.

Authors:  L Maria Belalcazar; Christie M Ballantyne; Wei Lang; Steven M Haffner; Julia Rushing; Dawn C Schwenke; F Xavier Pi-Sunyer; Russell P Tracy
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-04-21       Impact factor: 8.311

3.  Regulation of airway and alveolar epithelial cell apoptosis by p53-Induced plasminogen activator inhibitor-1 during cigarette smoke exposure injury.

Authors:  Shwetha K Shetty; Yashodhar P Bhandary; Amarnath S Marudamuthu; Daniel Abernathy; Thirunavukkarasu Velusamy; Barry Starcher; Sreerama Shetty
Journal:  Am J Respir Cell Mol Biol       Date:  2012-05-16       Impact factor: 6.914

4.  Induction of plasminogen activator inhibitor 1 gene expression in murine liver by lipopolysaccharide. Cellular localization and role of endogenous tumor necrosis factor-alpha.

Authors:  C Fearns; D J Loskutoff
Journal:  Am J Pathol       Date:  1997-02       Impact factor: 4.307

5.  Deficiency of plasminogen activator inhibitor 2 in plasma of patients with hereditary angioedema with normal C1 inhibitor levels.

Authors:  Kusumam Joseph; Baby G Tholanikunnel; Bethany Wolf; Konrad Bork; Allen P Kaplan
Journal:  J Allergy Clin Immunol       Date:  2015-09-26       Impact factor: 10.793

6.  Prognostic relevance of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in gastric cancer.

Authors:  H Ito; Y Yonemura; H Fujita; K Tsuchihara; T Kawamura; N Nojima; T Fujimura; H Nose; Y Endo; T Sasaki
Journal:  Virchows Arch       Date:  1996-02       Impact factor: 4.064

7.  Twenty-four-hour venoarterial extracorporeal membrane oxygenation without systemic heparinization in dogs.

Authors:  K Miyasaka; M Takata; R Muto
Journal:  Pediatr Surg Int       Date:  2013-09-21       Impact factor: 1.827

8.  Transcriptional regulation of plasminogen activator inhibitor type-1 mRNA in Hep G2 cells by epidermal growth factor.

Authors:  W E Hopkins; D R Westerhausen; B E Sobel; J J Billadello
Journal:  Nucleic Acids Res       Date:  1991-01-11       Impact factor: 16.971

Review 9.  Tissue-type plasminogen activator. A review of its pharmacology and therapeutic use as a thrombolytic agent.

Authors:  D Collen; H R Lijnen; P A Todd; K L Goa
Journal:  Drugs       Date:  1989-09       Impact factor: 9.546

10.  p53- and PAI-1-mediated induction of C-X-C chemokines and CXCR2: importance in pulmonary inflammation due to cigarette smoke exposure.

Authors:  Nivedita Tiwari; Amarnath S Marudamuthu; Yoshikazu Tsukasaki; Mitsuo Ikebe; Jian Fu; Sreerama Shetty
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2016-01-08       Impact factor: 5.464

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.